Displaying 69 out of 978 Biotech companies
 Filter
City
Country
Stage
Business Model
Industry
company score funding investors employees industries biz model city contact
Pheon Therapeutics HIRING

Antibody-Drug Conjugate specialist creating treatments for tough-to-treat cancers.

79
$120M · Series B TCG Crossover, Atlas Ventures, Brandon Capital 11 to 50 Health Tech, Biotech, Deep Tech, Pharma B2B London, UK •••••••••••@pheontx.com
SynOx Therapeutics HIRING

Developer of treatment for diffuse tenosynovial giant cell tumors.

68
$75M · Series B Bioqube Ventures, Medicxi, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Dublin, Ireland •••••••••••@synoxtherapeutics.com
Tubulis

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases.

68
$139M · Series B Nextech Invest, EQT Life Sciences, Andera Partners 11 to 50 Health Tech, Biotech, Deep Tech B2B Munich, Germany •••••••••••@tubulis.com
CN BioJUST ADDED HIRING

Provider of single and multi-organ microphysiological systems.

68
$21M · Series B CN Innovations 101 to 250 Health Tech, Biotech London, UK •••••••••••@cn-bio.com
ExpressionEditsJUST ADDED HIRING

AI-driven intronization technology developer.

68
$13M · Seed Octopus Ventures, Acequia Capital, Redalpine 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@expressionedits.com
Aqemia

Drug discovery platform.

64
$32M · Series A Wendel Growth, Bpifrance, Elaia 51 to 100 Biotech B2B Paris, France •••••••••••@aqemia.com
Causaly

Biomedical research discovery tool.

64
$60M · Series B ICONIQ Growth, Index Ventures, Pentech Ventures 51 to 100 Health Tech, AI, Biotech, Pharma B2B, SaaS London, UK •••••••••••@causaly.com
Beacon Therapeutics

Oophthalmic gene therapy company to treat blinding retinal illnesses.

64
$120M · Series A Syncona Partners LLP 1 to 10 Health Tech, Biotech London, UK •••••••••••@beacontx.com
Apollo Therapeutics

Portfolio of pharmaceutical research and discovery.

64
$33M · Series C Patient Square Capital, Rock Springs Capital, M&G Investments 1 to 10 Biotech, Pharma London, UK •••••••••••@apollotherapeutics.com
Eligo Bioscience

Gene-editing platform.

64
$30M · Series B Khosla Ventures, Sanofi Ventures, Bpifrance 11 to 50 Health Tech, Biotech Paris, France •••••••••••@eligo.bio
HEPHAISTOS-Pharma HIRING

Immunotherapies developer for cancer patient.

64
$4M · Seed Fournier-Majoie, France 2030, Elaia 1 to 10 Health Tech, Biotech Paris, France •••••••••••@hephaistos-pharma.fr
Bioptimus

Developer of a universal AI foundation model for biology.

64
$35M · Seed Frst, Bpifrance, Sofinnova Partners 1 to 10 AI, Biotech B2B, SaaS Paris, France •••••••••••@bioptimus.com
Cure51

Cancer survivors data analysis platform.

64
$16M · Seed Hitachi Ventures, Life Extension Ventures, Sofinnova Partners 11 to 50 Biotech, Data and Analytics B2B, SaaS Paris, France •••••••••••@cure51.com
Flindr TherapeuticsJUST ADDED HIRING

Precision oncology treatments developer.

64
$21M · Series A V-Bio Ventures 1 to 10 Health Tech, Biotech Amsterdam, Netherlands •••••••••••@flindrtx.com
Captain T CellJUST ADDED HIRING

Developer of next-generation T cells against solid tumors.

64
$9M · Seed Brandenburg Kapital, i&i Biotech Fund 1 to 10 Health Tech, Biotech Berlin, Germany •••••••••••@captaintcell.com
Adcendo HIRING

Antibody-drug conjugates (ADCs) developer for the treatment of cancer.

59
$17M · Series A RA Capital Management, Novo A/S, HealthCap 11 to 50 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@adcendo.dk
Adionics

Eco-friendly liquid-liquid direct lithium extraction (DLE) process developer.

59
$27M · Series B Bpifrance, Celeste Management, Sociedad Quimica Y Minera (SQM) 11 to 50 Climate Tech & Green Tech, Biotech B2B Paris, France •••••••••••@adionics.com
Baseimmune

AI vaccine algorithm developer.

59
$11M · Series A Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@baseimmune.co.uk
Mnemo Therapeutics

Biotechnology firm focused on life science advancements.

59
$89M · Series A Sofinnova Partners 101 to 250 Health Tech, Biotech B2B Paris, France •••••••••••@mnemo-tx.com
Onego Bio

Animal-free egg protein producer for food manufacturers.

59
$28M · Series A EIT Food, Agronomics, Tesi 11 to 50 Foodtech, Biotech B2B Helsinki, Finland •••••••••••@onego.bio
SparingVision

Biotechnology company focused on developing genomic medicines to treat blinding inherited retinal diseases.

59
$52M · Series A Ysios Capital 1 to 10 Health Tech, Biotech, Deep Tech B2B Paris, France •••••••••••@sparingvision.com
Vytrus Biotech HIRING

Active ingredient producer from plant stem cells for the cosmetics industry.

59
$2M · Seed Boyser SRL, ICF Capital 11 to 50 Biotech, Manufacturing B2B Barcelona, Spain •••••••••••@vytrus.com
Complement Therapeutics

Preclinical stage treatment for geographic atrophy.

59
$78M · Series A Forbion Capital Partners, Gimv 1 to 10 Biotech London, UK •••••••••••@complementtx.com
FA Bio

Discovery and development platform of superior microbial bioproducts.

59
$6M · Series A Pymwymic, Clean Growth Fund 1 to 10 Biotech London, UK •••••••••••@fungialert.com
Calluna Pharma

Developer of therapies for inflammatory and fibrotic diseases.

59
$81M · Series A Sarsia, p53, Forbion Capital Partners 11 to 50 Biotech, Pharma Oslo, Norway •••••••••••@callunapharma.com
IMU Biosciences

AI platform to map the human immune system.

59
$14M · Series A Life Extension Ventures, Molten Ventures 11 to 50 Health Tech, Biotech London, UK •••••••••••@imubiosciences.com
MIP Discovery

Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies.

59
$8M · Series A Mercia Asset Management 11 to 50 Health Tech, Biotech London, UK •••••••••••@mipdiscovery.com
Stanhope AI

Neuroscience-driven AI platform.

59
$2M · Seed Rockmount Capital, Moonfire Ventures, UCL Technology Fund 11 to 50 AI, Biotech B2B, SaaS London, UK •••••••••••@stanhopeai.com
MetyosJUST ADDED

Biosensors developer to combat chronic kidney disease.

59
$2M · Pre Seed Bpifrance, Kima Ventures, Cenitz 1 to 10 Health Tech, Biotech Paris, France •••••••••••@metyos.com
NeurosterixJUST ADDED

Advanced allosteric modulator therapeutics developer for neurological disorders.

59
$63M · Series A Xontogeny, Perceptive Advisors, Acorn Bioventures 1 to 10 Health Tech, Biotech Geneva, Switzerland •••••••••••@neurosterix.com
Sparxell

Developer of sustainable plant-based pigments.

59
$3M · Seed PDS Ventures, Circular Innovation Fund, L'Oreal 1 to 10 Biotech, Manufacturing B2C London, UK •••••••••••@sparxell.com
En Carta DiagnosticsJUST ADDED HIRING

Point-of-care diagnostic platform.

59
$1M · Pre Seed CentraleSupélec Venture 1 to 10 Health Tech, Biotech Paris, France •••••••••••@encarta.bio
CatalYm

Innovative immunotherapies developer for cancer patients.

54
$51M Forbion Capital Partners, Vesalius Biocapital Partners, Bayern Kapital 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@catalym.com
Charm Therapeutics

Platform using deep learning on 3D molecular structures to develop treatments for harmful proteins.

54
$50M · Series A Khosla Ventures, General Catalyst 1 to 10 Health Tech, AI, Biotech, Data and Analytics B2B London, UK •••••••••••@charmtx.com
Egle Therapeutics

Biotechnology firm developing immunotherapies for cancer and autoimmune diseases.

54
$46M Bioqube Ventures 11 to 50 Health Tech, Biotech B2B Paris, France •••••••••••@egle-tx.com
Eyevensys

Platform that develops bio factories to treat significant eye diseases sustainably.

54
$30M · Series B Karista, Pureos Bioventures 11 to 50 Health Tech, Hardware, Biotech, Manufacturing B2B Paris, France •••••••••••@eyevensys.com
Lindus Health

Clinical trials platform.

54
$18M · Series A Valar Ventures, Creandum, Seedcamp 11 to 50 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@lindushealth.com
MinervaX

Developer of prophylactic vaccine against Group B Streptococcus.

54
$57M · Series C EQT Partners, Novo A/S, OrbiMed 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@minervax.com
Mytos

Fully-automated cell manufacturing.

54
$19M · Series A Buckley Ventures, Wing Venture Capital, IQ Capital Partners 11 to 50 Biotech, Machine Learning B2B London, UK •••••••••••@mytos.bio
Orbis Medicines

Oral macrocycle drug discovery platform.

54
$28M · Seed Novo A/S, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@orbismedicines.com
Ori Biotech

Manufacturing platform designed to help patients access lifesaving treatments.

54
$30M · Series A Kindred Capital, Octopus Ventures, Amadeus Capital 1 to 10 Health Tech, Biotech, Manufacturing B2B London, UK •••••••••••@oribiotech.com
Quell Therapeutics

Cell therapy firm specializing in developing treatments using advanced cellular technology.

54
$45M · Series A AlbionVC, Point72 Ventures 101 to 250 Health Tech, Edtech, Biotech, Manufacturing B2B London, UK •••••••••••@quell-tx.com
ReViral

Biotechnology firm developing antiviral treatments for patients.

54
$44M · Series C Novo A/S, Andera Partners 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@reviral.co.uk
Tropic Biosciences

Platform specializing in developing new, high-yield tropical crop varieties and traits.

54
$28M · Series B Future Planet Capital 11 to 50 Agritech, Biotech, Deep Tech, Manufacturing B2B London, UK •••••••••••@tropicbioscience.com
Cultimate Foods HIRING

Fat ingredient producer for alternative meats.

54
$2M · Seed b.value AG, Life Science Valley Wachstumsfond, Kale United 1 to 10 Foodtech, Biotech B2B Berlin, Germany •••••••••••@cultimatefoods.com
Farmless

Fermentation process to produce protein from animals.

54
$5M · Seed Voyager Ventures, Revent, World Fund 1 to 10 Foodtech, Biotech B2C Amsterdam, Netherlands •••••••••••@farmless.com
AAVantgarde Bio

Gene therapies for inherited retinal disorders.

54
$65M · Series A Forbion Capital Partners 1 to 10 Biotech Milan, Italy •••••••••••@aavantgardebio.com
Astraveus

Automated bioprocessing system for the production of cell and gene therapies.

54
$18M · Seed AdBio Partners 11 to 50 Biotech Paris, France •••••••••••@astraveus.com
Umedeor

Platform to automate the clinical studies process.

54
$12M · Series A Playfair, Delin Ventures, 11.2 Capital 11 to 50 Health Tech, Biotech B2B London, UK •••••••••••@umed.io
Flarin

Patent-protected anti-inflammatory painkiller.

54
$6M · Series A ITV AdVentures 1 to 10 Biotech, Pharma B2C London, UK •••••••••••@flarin.co.uk
Genomes

User-owned genomics database platform.

54
$20M · Series A GEM Digital 1 to 10 Health Tech, Biotech B2C London, UK •••••••••••@genomes.io
Gradient Denervation Technologies

Medical devices for a transvascular treatment of pulmonary hypertension.

54
$14M · Series A Sofinnova Partners, Asabys Partners 1 to 10 Health Tech, Biotech Paris, France •••••••••••@gradientdenervation.com
Laverock Therapeutics

Gene silencing platform for the creation of programmable, allogeneic cell therapies.

54
$16M · Seed Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund 1 to 10 Health Tech, Biotech London, UK •••••••••••@laverocktx.com
Samabriva

Biomanufacturer of complex molecules.

54
$4M · Seed Meusinvest (Noshaq) 1 to 10 Biotech, Manufacturing Paris, France •••••••••••@samabriva.com
Hoba Therapeutics

Therapeutic protein developer for chronic neuropathic pain.

54
$24M · Series A Medical Incubator Japan, Borean Innovation, Novo A/S 1 to 10 Health Tech, Biotech Copenhagen, Denmark •••••••••••@hobatherapeutics.com
Vico Therapeutics HIRING

Medicine for rare neurological diseases.

54
$58M · Series B Droia Ventures, Ackermans & van Haaren, Idinvest Partners 11 to 50 Health Tech, Biotech B2C The Hague, Netherlands •••••••••••@vicotx.com
Paques Biomaterials

Polyhydroxyalkanoates (PHA) producer.

54
$15M · Seed NV NOM, Invest-NL 1 to 10 Biotech Amsterdam, Netherlands •••••••••••@paquesbiomaterials.nl
Quantistry

Cloud-native chemical simulation platform.

54
$3M · Seed Chemovator, Ananda Impact Ventures, IBB Ventures 11 to 50 Biotech, Cloud B2B, SaaS Berlin, Germany •••••••••••@quantistry.com
Hexigone InhibitorsJUST ADDED HIRING

Sustainable corrosion inhibitors manufacturer.

54
$1M · Seed Oxford Innovation Finance, Waterspring Ventures, Development Bank of Wales 1 to 10 Biotech, Manufacturing B2B London, UK •••••••••••@hexigone.com
LimulaJUST ADDED HIRING

Gene therapy platform.

54
$6M · Seed Life Extension Ventures, Zühlke Group, Oxford Seed Fund 1 to 10 Health Tech, Biotech Geneva, Switzerland •••••••••••@limula.ch
Nouscom

Viral vector-based cancer vaccines developer.

51
$82M · Series C Bpifrance, 5AM Ventures, Abingworth 1 to 10 Health Tech, Biotech B2C Basel, Switzerland •••••••••••@nouscom.com
Achilles Therapeutics

Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

50
$17M · Seed AlbionVC, Boxer Capital, Syncona Partners LLP 101 to 250 Health Tech, Biotech B2B London, UK •••••••••••@achillestx.com
ADmit Therapeutics

Early detection of Alzheimer's disease (AD) technology.

50
$5M · Series A WA4STEAM, EIC Accelerator, Ship2B 1 to 10 Health Tech, Biotech, Pharma B2B Barcelona, Spain •••••••••••@admit-therapeutics.com
AMSilk

Developer of bio-fabricated silk protein materials.

50
$27M · Series C Novo A/S 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@amsilk.com
Ariceum Therapeutics

Diagnosis and treatment of hard-to-treat cancers.

50
$24M · Series A Earlybird Venture Capital, Andera Partners, HealthCap 11 to 50 Health Tech, Biotech, Pharma B2B Berlin, Germany •••••••••••@ariceum-therapeutics.com
Bactolife

Producer of gut health binding proteins.

50
$32M · Series A Bill & Melinda Gates Foundation, Novo A/S 1 to 10 Biotech, Pharma B2B Copenhagen, Denmark •••••••••••@bactolife.com
Daye

Gynecological health company creating products and services for vaginal treatment.

50
$5M · Seed Khosla Ventures, Index Ventures, Kindred Capital 11 to 50 Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis B2C London, UK •••••••••••@yourdaye.com
EnginZyme

Bio alternative to fossil-based and energy–intensive chemical production.

50
$22M · Series B Sofinnova Partners, SEB Venture Capital, Industrifonden 51 to 100 Health Tech, Biotech B2B Stockholm, Sweden •••••••••••@enginzyme.com
Enterome

Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.

50
$3M · Series F The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science 51 to 100 Health Tech, Biotech, Deep Tech, Pharma B2B Paris, France •••••••••••@enterome.com
OTHER INDUSTRIES
Other Biotech startups by location